Veracyte Inc. (NASDAQ: VCYT) Chief Financial Officer Rebecca Chambers executed two stock sales on March 4, 2026, disposing of a combined 18,341 shares of the company’s common stock for total proceeds of $662,869.
The trades were split into two transactions. One block of 4,400 shares sold at a weighted average price of $35.5476, with individual execution prices between $35.00 and $35.99. A second block of 13,941 shares moved at a weighted average of $36.3288, at prices ranging from $36.01 to $36.55. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan that Chambers adopted on August 21, 2025.
After these dispositions, Chambers holds 131,196 shares of Veracyte directly. At the time the report cited, Veracyte’s stock was trading at $33.85, down 20% year-to-date but still roughly 50% higher than its 52-week low of $22.61.
The company’s most recent public filings and analyst notes cited a profitable trailing twelve months for Veracyte, according to InvestingPro analysis. That profit record sits alongside the company’s fourth-quarter 2025 financial report, which topped analyst expectations: Veracyte posted earnings per share of $0.53 versus a $0.39 consensus and reported quarterly revenue of $141 million compared with forecasts of $132.43 million.
Management also reaffirmed its revenue and adjusted EBITDA margin guidance for 2026 in conjunction with the quarterly results. The market reaction and analyst responses were mixed. Needham raised its price target on Veracyte to $48 from $44 while maintaining a Buy rating. Morgan Stanley moved in the opposite direction on price target, lowering it to $37 from $48 and continuing to rate the stock Underweight.
The executed sales and the company’s recent financial disclosures provide concurrent signals for investors to consider: insider liquidity under a Rule 10b5-1 arrangement, a profitable trailing year per InvestingPro, and a Q4 beat accompanied by reaffirmed guidance and divergent analyst valuation outlooks.
Context and next steps
Because the sales were conducted under a pre-established 10b5-1 plan, they reflect transactions scheduled in advance rather than necessarily indicating an immediate change in insider sentiment. Investors tracking insider activity and near-term catalysts may weigh these sales alongside the company’s reaffirmed guidance and the split analyst responses when assessing valuation and risk.